Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Metastatic Castration Resistant Prostate Cancer 1 Breast Neoplasms 1

Interventions

pembrolizumab 162 Carboplatin 144 Paclitaxel 125 Cyclophosphamide 93 130-nm albumin-bound paclitaxel 66 Capecitabine 63 Gemcitabine 54 Doxorubicin 49 Albumin-Bound Paclitaxel 45 Taxes 42 atezolizumab 40 Cisplatin 38 Nivolumab 34 sacituzumab govitecan 32 olaparib 32 Epirubicin 32 Docetaxel 28 eribulin 27 Specimen Handling 26 Bevacizumab 26 durvalumab 25 camrelizumab 23 Drug Therapy 22 Biopsy 22 Magnetic Resonance Spectroscopy 21 toripalimab 18 Radiotherapy 17 spartalizumab 16 Everolimus 15 fludarabine 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Triple Negative Breast Neoplasms × sabizabulin × Clear all

NCT05008510 2022-02-08

VERU-111

Veru Inc.

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡